GlassScriptPhysician profile
Kurt D Olinde
NPI 1528170255
$1,032.35
in general payments reported to CMS, 2019-2025
19 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.17 · 2021: $36.04 · 2022: $91.28 · 2023: $215 · 2024: $260 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.64 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $148.93 | 2022-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $126.43 | 2021-2024 | |
| Lexicon Pharmaceuticals, INC. | $113.85 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $98.83 | 2023-2025 | |
| Inspire Medical Systems, INC. | $98.00 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.86 | 2024 | Lifevest |
| Lilly USA, LLC | $52.73 | 2025 | Jardiance, Mounjaro |
| Ardelyx, INC. | $49.74 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.38 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $40.51 | 2021-2022 | |
| Pfizer INC. | $39.87 | 2019-2025 | |
| Novo Nordisk INC | $28.86 | 2022-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $23.97 | 2023 | Keveyis |
| Edwards Lifesciences Corporation | $22.20 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $19.92 | 2025 | Airsupra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.06 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.46 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.42 | 2019 | |
| Exact Sciences Corporation | $15.33 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Olinde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.